Tumor-Infiltrating lymphocyte grade IDs melanoma survival

June 20, 2012
Tumor-Infiltrating lymphocyte grade IDs melanoma survival
Tumor-infiltrating lymphocyte grade is an independent predictor of melanoma-specific survival and sentinel lymph node status in patients with localized primary cutaneous melanoma, according to a study published online June 18 in the Journal of Clinical Oncology.

(HealthDay) -- Tumor-infiltrating lymphocyte (TIL) grade is an independent predictor of melanoma-specific survival and sentinel lymph node (SLN) status in patients with localized primary cutaneous melanoma, according to a study published online June 18 in the Journal of Clinical Oncology.

To investigate whether the density and distribution of TILs independently predicts SLN status and survival, Farhad Azimi, of the Melanoma Institute Australia in Sydney, and colleagues reviewed data from 1,865 patients with a single localized primary cutaneous melanoma ≥0.75 mm in thickness.

The researchers observed an inverse association between TIL grade and tumor thickness, mitotic rate, and Clark level. Sixty-one percent of patients underwent a SLN biopsy and 22.1 percent were positive. SLN positivity decreased with increasing TIL grade, ranging from 27.8 percent for TIL grade 0 to 5.6 percent for TIL grade 3 (P < 0.001). Decreasing age, decreasing TIL grade, ulceration, increasing tumor thickness, satellitosis, and increasing mitoses were significant predictors of SLN positivity. Independent predictors of melanoma-specific survival were tumor thickness, ulceration, satellitosis, mitotic rate, TIL grade, and sex. Survival was 100 percent in those with TIL grade 3.

"Ultimately, a greater understanding of the mechanisms controlling TILs in melanoma may provide avenues for developing important new immunotherapeutic strategies for patients with ," the authors write.

Explore further: Women have clear melanoma survival advantage over men

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Women have clear melanoma survival advantage over men

May 1, 2012
(HealthDay) -- Women with localized melanoma have a consistent advantage over men of approximately 30 percent for survival and progression, according to a study published online April 30 in the Journal of Clinical Oncology.

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012
(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

Ipilimumab active in advanced melanoma with brain mets

March 27, 2012
(HealthDay) -- For some patients with advanced melanoma and brain metastases, ipilimumab is active, according to the results of a phase 2 study published online March 27 in The Lancet Oncology.

Invasive melanoma may be more likely in children than adults

October 5, 2011
A Johns Hopkins Children's Center study of young people with melanoma, a deadly form of skin cancer, has found that some children have a higher risk of invasive disease than adults.

Sentinel node biopsy safe, effective in head and neck melanomas

August 5, 2011
A common technique for determining whether melanoma has spread can be used safely and effectively even in tumors from the head and neck area, according to a new study from the University of Michigan Comprehensive Cancer Center.

Recommended for you

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.